

SARS-CoV-2 (COVID-19) vaccination, affected on post-acute-COVID-19-sequelae symptoms (long COVID-19)

Volume 9 Issue 2 - 2022

Editorial

Currently, few prospective data that explore the biological mechanisms of the effect of SARS-CoV-2 (COVID-19) vaccination on the persistent symptoms, “long-COVID 19” or “post-acute sequelae of COVID (PASC)”, including compared antibody dynamics between those with and without PASC.^{1,2} PASC is defined by symptoms persisting more than 4 weeks after a confirmed or probable COVID-19, without any confirmed alternative diagnosis.¹ Around 52.8 % of the patients reported a global effect on symptoms after the vaccine injection, corresponding to a worsening in around 31 % and an improvement in around 21.8 %.¹ No differences based on the vaccine type used were detected.¹ Fear of worsening PASC symptoms (55.9 %) were the most common reasons for the SARS-CoV-2 (COVID-19) vaccination postponing.¹ Around 58.9 % of the enrolled subjects developed PASC after at least 3 months of follow-up.² Age, sex, obesity status, and time since illness onset of the participants have no significantly statistical differences.² Among PASC participants, they revealed the median half-life of RBD- and spike-binding IgG levels of 181 (95 % CI: 147-230) and 233 (95 % CI: 183-324) days, whereas among those without PASC demonstrated 144 (95 % CI: 113-196) and 170 (95 % CI: 125-252) days, respectively.²

Conclusion

In conclusion, the majority of PASC patients were well tolerated to SARS-CoV-2 (COVID-19) vaccine and have good immunogenicity. However, further investigations are urgently needed to confirm the COVID-19-vaccine-related strong evidence on improvement of PASC symptoms.

Attapon Cheepsattayakorn,^{1,2}
Ruangrong Cheepsattayakorn,³ Porntep
Siriwanarangsun¹

¹Faculty of Medicine, Western University, Thailand

²10th Zonal Tuberculosis and Chest Disease Center, Thailand

³Department of Pathology, Faculty of Medicine, Chiang Mai University, Thailand

Correspondence: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, 143 Sridornchai Road Changklan Muang Chiang Mai 50100, Thailand, Tel 66 53 140767, 66 53 276364, Fax 66 53 140773, 66 53 273590, Email Attapon1958@gmail.com

Received: July 4, 2022 | **Published:** July 5, 2022

References

1. Scherlinger M, Pijenburg L, Chatelus E, et al. Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG Study. *Vaccines*. 2022;10(1):46.
2. Wynberg E, Han AX, Boyd A, et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): a prospective cohort study. *Vaccine*. 2022. In Press.